Kaneka Corporation (FRA:KKA)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.02B +30.1% |
| Revenue (ttm) | 4.50B +3.5% |
| Net Income | 192.01M +58.2% |
| EPS | 3.13 +62.8% |
| Shares Out | n/a |
| PE Ratio | 10.55 |
| Forward PE | n/a |
| Dividend | 1.00 (3.10%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | n/a |
| Open | 33.60 |
| Previous Close | 34.20 |
| Day's Range | 32.40 - 33.60 |
| 52-Week Range | 21.40 - 35.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About Kaneka
Kaneka Corporation engages in the manufacture and sale of polyvinyl chloride (PVC), crosslinked PVC, PVC-PVAc polymers, paste PVC, acryl grafted-vinyl chloride copolymer, and chlorinated PVC in Japan, Asia, North America, Europe, and internationally. It offers impact modifiers, processing aids, specialty additives, toughener for thermosetting resins, silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, biodegradable polymer, engineering resin for injection molding, acrylic film, and isobutylene-based thermoplastic el... [Read more]
Financial Performance
In fiscal year 2026, Kaneka's revenue was 811.64 billion, an increase of 0.55% compared to the previous year's 807.20 billion. Earnings were 30.98 billion, an increase of 22.40%.
Financial numbers in JPY Financial StatementsNews
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kaneka Medical America LLC , a subsidiary company of Kaneka Corporation , innovating embolization coil technology for neurovascular therapies, today announc...